Skip to main content
Fig. 6 | Biomarker Research

Fig. 6

From: Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia

Fig. 6

Anti-leukemia activity of sitravatinib against AML primary blasts. A-D Dose–response curves of primary AML patient samples diagnosed as FLT3-ITD treated with sitravatinib, gilteritinib or quizartinib at indicated concentrations for 48 h. E–G Western blot analysis of p-FLT3, p-STAT5, p-AKT, p-ERK 1/2 in AML blasts harboring FLT3-ITD after 6-h sitravatinib treatment. H Schematic representation of the PDX model experiments. I The percentage of human CD45 positive cells in PB of PDX mice detected by flow cytometry on day 39 (n = 3 mice per group) and day 82 (n = 5 or 6 mice per group). J The percentage of human CD45 positive cells in BM and SP of PDX mice detected by flow cytometry on day 120 (n = 3 mice per group). Error bars indicate mean ± standard error, *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page